Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and ß-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for... Biopharmaceuticals, FDA Aruvant Sciences, sickle cell, thalassemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news